

1631  
IFW



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANTS: Bodlog, et al

EXAMINER: Cheyne D. Ly

SERIAL NUMBER: 10/038,854

ART UNIT: 1631

FILING: DATE: December 31, 2001

FOR: PROTEINS AND NUCLEIC ACIDS ENCODING SAME

**Mail Stop IDS**

Commissioner of Patents

P.O. Box 1450

Alexandria, VA 22313-1450

**TRANSMITTAL LETTER**

Transmitted herewith for filing in the present application are the following documents:

1. Supplemental Information Disclosure Statement (2 pages), in duplicate;
2. Modified Form 1449/PTO (1 page) in duplicate;
3. Copies of Cited references C280-C288 and;
4. Return Postcard

No fee is believed to be due at this time. However, the Commissioner is authorized to charge any additional fees that may be due to Deposit Account No.502648, Reference No. Cura 530 (21402-230). A duplicate copy of this transmittal letter is enclosed.

If the enclosed papers are considered incomplete, the Mail Room and/or the Application Branch is respectfully requested to contact the undersigned at 203/974-6303, New Haven, Connecticut.

Respectfully submitted,

Date: March 20, 2004

George Yahwak, Reg. No. 26,824  
c/o CuraGen Corporation  
555 Long Wharf Drive  
New Haven, CT 06511  
Tel: (203) 974-6303  
Fax: (203) 401-3351



**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

APPLICANT(S): Boldog, et al.

EXAMINER: Cheyne D. Ly

SERIAL NUMBER: 10/038,854

ART UNIT: 1631

FILING DATE: December 31, 2001

FOR: PROTEINS AND NUCLEIC ACIDS ENCODING SAME

**Mail Stop IDS**  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

**SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT**

Pursuant to the duty disclosure under 37 C.F.R. §§ 1.56, 1.97 and 1.98, Applicants hereby make of record the documents attached modified Form PTO-1449.

Following review of the last Official Action in this application, to which Applicants have prepared and submitted a response to the Examiner, Applicants wish to provide a Supplemental Information Disclosure Statement under the provisions of 37 CFR.

It is respectfully requested that the Examiner consider completely the cited information, along with any other information, in reaching a determination concerning the patentability of the present claims, and signs the enclosed form PTO-1449 to evidence that the cited information has been fully considered by the Patent and Trademark Office during the examination of this application.

By Submitting this Information Disclosure Statement, the Applicant makes no representation that: (1) a search has been performed, or that more relevant information


does not exist; and (2) the information cited in the Statement is, or is considered to be, material to patentability as defined in 37 C.F.R. § 1.56(b).

The order of presentation of the references should not be constructed as an indication of the importance of the references. The Examiner is urged to form his/her own conclusion regarding the relevance of the cited information.

While Applicants do not believe any additional fees are required as a result of this submission, should the Examiner determine otherwise, the Examiner is authorized to debit Deposit Account No. 502648 in the amount of such required fees, citing reference Cura 530 (21402-230).

Respectfully submitted,

Date: May 20, 2004



---


George Yahwak, Reg. No. 26,824  
c/o CuraGen Corporation  
555 Long Wharf Drive  
New Haven, CT 06511  
Tel: (203) 974-6303  
Fax: (203) 401-3351

Express Mail No. EI#####US  
Date of Deposit: \_\_\_\_\_

Page 1 of 1

Please type a plus sign (+) in this box

+



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

PTO/SB (12-97)  
Approved for use through 9/30/00. OMB 0651-0031  
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

<b>Modified Form 1449/PTO</b>  <b>SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)	<b>Application Number</b>	10/038,854
	<b>Filing Date</b>	12/31/01
	<b>First Named Inventor</b>	Boldog, et al.
	<b>Group Art Unit</b>	1631
	<b>Examiner Name</b>	Cheyne D. Ly
	<b>Attorney Docket Number</b>	Cura 530 (21402-230)

U.S. PATENT DOCUMENTS							
Exam Initials	Cite No.	U.S. Patent Document No.	Issue Date	Name of Patentee(s) or Applicant(s)	Class	Sub Class	Filing Date if Appropriate
	A1						

FOREIGN PATENT DOCUMENTS							
Exam Initials	Cite No.	Foreign Patent Document Office Number		Name of Patentee(s) or Applicant(s)	Date of Publication	Translation Yes No	
	B1						

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS		
Exam Initials	Cite No.	Name of Author, Title (when appropriate), Publication, Volume, Page(s), Date, Etc.
	C280	SWALL (SPTR) Accession Number: Q9JLC1 (1-OCT-2000).
	C281	SWALL (SPTR) Accession Number: Q9NV77 (1-OCT-2000).
	C282	SWALL (SPTR) Accession Number: Q9NVW1 (1-OCT-2000).
	C283	SWALL (SPTR) Accession Number: Q9NZJ2 (1-OCT-2000).
	C284	SWALL (SPTR) Accession Number: Q9P273 (1-OCT-2000).
	C285	SWALL (SPTR) Accession Number: Q9WTS6 (1-NOV-1999).
	C286	Anderson, R. A., R. S. Byrum, et al. (1994). "Mutations at the lysosomal acid cholesteryl ester hydrolase gene locus in Wolman disease." Proc Natl Acad Sci U S A 91(7): 2718-22.
	C287	Ben-Zur, T., E. Feige, et al. (2000). "The mammalian Odz gene family: homologs of a Drosophila pair-rule gene with expression implying distinct yet overlapping developmental roles." Dev Biol 217(1): 107-20.
	C288	Nagase, T., R. Kikuno, et al. (2000). "Prediction of the coding sequences of unidentified human genes. XVII. The complete sequences of 100 new cDNA clones from brain which code for large proteins in vitro." DNA Res 7(2): 143-50.

\* a copy of this reference is not provided as it was previously cited by or submitted to the office in a prior application, Serial No. \_\_\_\_\_, filed \_\_\_\_\_, and relied upon for an earlier filing date under 35 U.S.C. §120 (continuation, continuation-in-part, and divisional applications).

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered.

Include copy of this form with next communication to applicant.